Cargando…

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Caterina, Raffaele, Ageno, Walter, Boriani, Giuseppe, Colonna, Paolo, Ghirarduzzi, Angelo, Patti, Giuseppe, Rossini, Roberta, Rubboli, Andrea, Schinco, Piercarla, Agnelli, Giancarlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350200/ https://www.ncbi.nlm.nih.gov/pubmed/28194578 http://dx.doi.org/10.1007/s12325-017-0488-9

Ejemplares similares

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

COVID-19, coagulopathy and venous thromboembolism: more questions than answers
por: Marietta, Marco, et al.
Publicado: (2020)

Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology
por: Patti, Giuseppe, et al.
Publicado: (2020)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Tellor, Katie B, et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
por: Camporese, Giuseppe, et al.
Publicado: (2020)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

COVID-19, coagulopathy and venous thromboembolism: more questions than answers—comment
por: Ponzetto, Antonio, et al.
Publicado: (2020)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study
por: Grifoni, Elisa, et al.
Publicado: (2022)

LAPAROSCOPIC ANTIREFLUX SURGERY: WERE OLD QUESTIONS ANSWERED? PARTIAL OR TOTAL FUNDOPLICATION?
por: Allaix, Marco Ettore, et al.
Publicado: (2023)

Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
por: Hara, Nobuhiro, et al.
Publicado: (2017)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

Medical Device Regulations for custom-made devices: answers to ten important questions
por: I. J. Green, James
Publicado: (2022)

COVID-19 pandemic: ten research questions Africa must answer for itself
por: Bonney, Evelyn Y, et al.
Publicado: (2020)

Should we measure the central venous pressure to guide fluid management? Ten answers to 10 questions
por: De Backer, Daniel, et al.
Publicado: (2018)

A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2022)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Questions & Answers
por: CERN. Geneva
Publicado: (2019)

Questions and answers
por: Jones, Rhodri, et al.
Publicado: (2023)

Questions and answers
por: Jones, Rhodri, et al.
Publicado: (2022)

Questions and Answers
Publicado: (1887)

The Question Answered
por: Smith, C. Carleton
Publicado: (1881)

Questions and Answers
Publicado: (1895)

Ten Letters, with Answers
Publicado: (1873)

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm
por: Mochimaru, Takao, et al.
Publicado: (2017)

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
por: Ramacciotti, Eduardo, et al.
Publicado: (2018)

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
por: Stacy, Zachary A., et al.
Publicado: (2016)

Recent advances in the management of venous thromboembolism
por: Ageno, Walter
Publicado: (2010)

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Automatic question answering for multiple stakeholders, the epidemic question answering dataset
por: Goodwin, Travis R., et al.
Publicado: (2022)

Questions and Answers to panellists
por: Wijnands, Thijs
Publicado: (2019)

Questions and Answers to panellists
por: Purcell, Andrew Robert
Publicado: (2018)

Questions & answers to panellists
por: CERN. Geneva
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ggm9cqa044hg6t7e13nsjueo7n